A. Pochtovyi

发表

Sputnik V Effectiveness against Hospitalization with COVID-19 during Omicron Dominance

E. D. Belyaeva, V. Gushchin, I. Grigoriev, 2022, Vaccines.

Dynamics of SARS-CoV-2 Major Genetic Lineages in Moscow in the Context of Vaccine Prophylaxis

E. D. Belyaeva, V. Gushchin, A. Gintsburg, 2022, International journal of molecular sciences.

Estimation of anti-orthopoxvirus immunity in Moscow residents and potential risks of spreading Monkeypox virus

E. D. Belyaeva, V. Gushchin, I. Grigoriev, 2022, Frontiers in Immunology.

The rise and spread of the SARS-CoV-2 AY.122 lineage in Russia

E. Nabieva, V. Gushchin, A. Samoilov, 2022, Virus evolution.

Microbiological Characteristics of Some Stations of Moscow Subway

A. Shchetinin, V. Gushchin, A. Gintsburg, 2022, Biology.

A Deep Look Into COVID-19 Severity Through Dynamic Changes in Blood Cytokine Levels

V. Gushchin, A. Gintsburg, D. Logunov, 2021, Frontiers in Immunology.

The rise and spread of the SARS-CoV-2 AY.122 lineage in Russia

E. Nabieva, A. Samoilov, A. Komissarov, 2021, medRxiv.

SARS-CoV-2 Aerosol and Surface Contamination in Health Care Settings: The Moscow Pilot Study

A. Shchetinin, V. Gushchin, A. Gintsburg, 2021 .

A Strategy for the Rapid Development of a Safe Vibrio cholerae Candidate Vaccine Strain

V. Gushchin, D. Karpov, A. Tkachuk, 2021, International journal of molecular sciences.

Engineered Endolysin LysECD7-SMAP Reveals Antimicrobial Synergy with Antibiotics and Restores Sensitivity in Gram-negative Pathogens

V. Gushchin, I. Grigoriev, A. Tkachuk, 2022, Applied Biochemistry and Microbiology.

Discovering the Potentials of Four Phage Endolysins to Combat Gram-Negative Infections

E. V. Usachev, V. Gushchin, I. Grigoriev, 2021, Frontiers in Microbiology.

Neutralizing Activity of Sera from Sputnik V-Vaccinated People against Variants of Concern (VOC: B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.3) and Moscow Endemic SARS-CoV-2 Variants

A. Shchetinin, V. Gushchin, O. Voronina, 2021, Vaccines.

Revaccination in Age-Risk Groups with Sputnik V Is Immunologically Effective and Depends on the Initial Neutralizing SARS-CoV-2 IgG Antibodies Level

V. Gushchin, A. Gintsburg, D. Logunov, 2022, Vaccines.

Sputnik Light booster after Sputnik V vaccination induces robust neutralizing antibody response to B.1.1.529 (Omicron) SARS-CoV-2 variant

V. Gushchin, F. Izhaeva, A. Tukhvatulin, 2021, medRxiv.

Sputnik Light and Sputnik V Vaccination Is Effective at Protecting Medical Personnel from COVID-19 during the Period of Delta Variant Dominance

V. Gushchin, A. Gintsburg, D. Logunov, 2022, Vaccines.

Contamination of Hospital Surfaces with Bacterial Pathogens under the Current COVID-19 Outbreak

V. Gushchin, A. Gintsburg, A. Tkachuk, 2021, International journal of environmental research and public health.

Development and characterization of chimera of yellow fever virus vaccine strain and Tick-Borne encephalitis virus

A. Shchetinin, A. Gintsburg, D. Logunov, 2023, PloS one.

One-shot immunization with Sputnik Light (the first component of Sputnik V vaccine) is effective against SARS-CoV-2 Delta variant: efficacy data on the use of the vaccine in civil circulation in Moscow

A. Shchetinin, B. Naroditsky, A. Komissarov, 2021, medRxiv.

In Vitro Efficacy of Antivirals and Monoclonal Antibodies against SARS-CoV-2 Omicron Lineages XBB.1.9.1, XBB.1.9.3, XBB.1.5, XBB.1.16, XBB.2.4, BQ.1.1.45, CH.1.1, and CL.1

D. Logunov, A. Siniavin, I. Dolzhikova, 2023, Vaccines.

Characterisation of the COVID-19 epidemic process in Moscow and search for possible determinants of the trends of the observed changes

D. Logunov, D. Kleymenov, A. Pochtovyi, 2023, Journal of microbiology, epidemiology and immunobiology.